
    
      The study will evaluate three treatment regimens in three arms: a belvarafenib monotherapy
      arm (Belva arm) of up to 15 patients; a belvarafenib plus cobimetinib arm (Belva + Cobi arm)
      in an initial dose-finding phase followed by an expansion phase and a belvarafenib plus
      cobimetinib plus atezolizumab arm (Belva + Cobi + Atezo arm) in a run-in phase followed by an
      expansion phase.
    
  